Clinical Trials Logo

Filter by:
NCT ID: NCT02705482 Completed - Clinical trials for Select Advanced Solid Tumors

A Study to Evaluate MEDI0562 in Combination With Immune Therapeutic Agents in Adult Subjects With Advanced Solid Tumors

Start date: March 30, 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate MEDI0562 in combination with immune therapeutic agents in adult subjects with select advanced solid tumors.

NCT ID: NCT02704429 Completed - Pemphigus Vulgaris Clinical Trials

A Study of PRN1008 in Adult Patients With Pemphigus Vulgaris

Start date: January 22, 2016
Phase: Phase 2
Study type: Interventional

Open-label cohort study in adult patients with newly diagnosed or relapsing pemphigus vulgaris, with intra-patient dose-adjustment based on clinical response and BTK occupancy, and with conventional immunosuppressive "rescue treatment", if indicated. The duration of therapy in Part A will be 12 weeks, followed by 12 weeks of follow up. The extension phase, Part B includes 24 weeks of therapy, followed by 4 weeks of follow-up.

NCT ID: NCT02704364 Completed - Clinical trials for Primary Sclerosing Cholangitis

Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis

Start date: March 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and activity of NGM282 in patients with Primary Sclerosing Cholangitis.

NCT ID: NCT02704273 Completed - Clinical trials for X-linked Myotubular Myopathy

A Clinical Assessment Study in X-Linked Myotubular Myopathy (XLMTM) Subjects

INCEPTUS
Start date: July 2016
Phase:
Study type: Observational

This is a pre-Phase 1 prospective, non interventional clinical assessment study to evaluate XLMTM subjects aged 3 years and younger. Many of these clinically relevant measures have not yet been routinely assessed in this population and may provide important insight on the natural history of XLMTM and for future evaluation of potential therapies.

NCT ID: NCT02704260 Completed - Genetic Syndrome Clinical Trials

Genetic of SportS Induced Endofibrotic Remodeling

GOSSER
Start date: March 2, 2016
Phase: N/A
Study type: Interventional

search for a genetic cause of vascular endofibrose

NCT ID: NCT02704247 Completed - Healthy Clinical Trials

CARDIOSPACE Evaluation in Healthy Volunteers

CARDIOSPACE
Start date: April 2014
Phase: N/A
Study type: Interventional

The aim of this porject is to test the Cardiospace system that integrates several medical devices to monitor the cardiovascular system: - ECG - Brachial blood pressure - Continuous finger blood pressure - Ultrasound - Laser doppler + iontophoresis Cardiospace will be used in space station to monitor the cardiovascular system of astronauts for research purpuse.

NCT ID: NCT02703922 Completed - Clinical trials for Giant Cell Arteritis

Validation of a Diagnostic Algorithm of Giant Cell Arteritis

ECHORTON
Start date: August 29, 2016
Phase: N/A
Study type: Interventional

Giant cell arteritis (GCA or temporal arteritis or cranial arteritis) or Horton disease is a vasculitis that occurs in older adults, affecting vessels of medium and large caliber. The diagnosis of GCA is a challenge for general practitioners and specialists. Since 1970, it is based on a combination of clinical, biological and histological signs. Temporal artery biopsy (TAB) was the reference method until recently. However, TAB has many drawbacks. Therefore, researches of the past 20 years have been intended to develop alternative diagnostic methods. This was notably the case of the color Doppler ultrasound (CDU) since the description by Wolfgang Schmidt of the halo sign. Although European and British recommendations put CDU as second line method, many authors suggest the possibility to do without TAB in many cases. In addition, many practitioners believe that it is not "ethical" to use an invasive unprofitable procedure like TAB, and have already been using CDU in their routine practice. However, no diagnostic algorithm validating this approach in a prospective series has been published to date. Therefore, the present study aim at validating a diagnostic algorithm of giant cell arteritis using color Doppler imaging of temporal arteries and cervicocephalic axes as first screening method.

NCT ID: NCT02703857 Completed - Clinical trials for Antibiotic Prophylaxis Surgery

Study of Repeated Cefoxitin Administration in Major Abdominal Surgery Using a Microdialysis Technique

PROPHYLOXITINE
Start date: February 2016
Phase: Phase 4
Study type: Interventional

The surgical site infection is one of the most important causes of postoperative morbidity. The appropriate antibiotic prophylaxis is one of the most effective ways to prevent surgical site infections. The recommendations of the French Society of Anesthesia Resuscitation on antibiotic prophylaxis in long surgeries are based on low documentation, including frequency and dosage of reinjection. The main objective of the study is to describe the tissue and plasma pharmacokinetics of cefoxitin after repeated injections. This is an open monocentric study (phase 4) including adults aged 18 to 80 years in need of major abdominal surgery whose foreseeable time exceeds 4 hours and justifying an antibiotic prophylaxis by cefoxitin. They receive 2 g cefoxitin parenterally at least 30 minutes before the incision and then every 2 hours until closing. The primary endpoints are: - Total and plasma free concentrations of cefoxitin 0, 10, 30, 60, 90, 120 minutes after start of each infusion cefoxitin - Tissue free concentrations of cefoxitin every 20 minutes after the start of the first infusion cefoxitin until skin closure - Urinary concentrations of cefoxitin

NCT ID: NCT02703740 Completed - Aesthetics Clinical Trials

Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds

ECLAH
Start date: January 11, 2016
Phase: N/A
Study type: Interventional

This study evaluates the injection of a hyaluronic acid dermal filler with lidocaine 0.3% in the treatment of nasolabial folds (NLF). Each patient will receive 1 concentration in a NLF (20 mg/mL) and an other concentration in the other NLF (24 mg/mL).

NCT ID: NCT02703038 Completed - Shock, Cardiogenic Clinical Trials

French Observatory on the Management of Cardiogenic Shock in 2016

FRENSHOCK
Start date: April 2016
Phase:
Study type: Observational

Cardiogenic shock (CS) is defined as an organ hypoperfusion secondary to low cardiac output. Catches diagnostic management, and therapeutic monitoring of these patients remain highly variable from one center to another and even from one doctor to another within the same team. The management protocols are often not standardized or non-existent. It appears therefore necessary to make an inventory of the management practices of the CS in France in 2016, prerequisite to a common work of standardization of practices and the creation of specialized networks to support these complex patients.